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Abstract (247 words) 
Objective: To determine the change in non-invasive ventilation (NIV) use over time in infants 
born at <32 weeks’ gestation and the associated clinical outcomes. 
 
Study design: Retrospective cohort study using routinely recorded data from the National 
Neonatal Research Database of infants born at <32 weeks admitted to neonatal units in 
England and Wales from 2010 to 2017.  
 
Results: In 56,537 infants, NIV use increased significantly between 2010 and 2017 
(Continuous Positive Airway Pressure (CPAP) from 68.5% to 80.2% in 2017 and high flow 
nasal cannula (HFNC) from 14% to 68% respectively) (p<0.001)). Use of NIV as the initial 
mode of respiratory support also increased (CPAP, 21.5% to 28.0%; HFNC, 1% to 7%; 
(p<0.001)).  
 
HFNC was used earlier, and for longer, in those who received CPAP or mechanical 
ventilation.  HFNC use was associated with decreased odds of death before discharge (aOR 
0.19, 95% CI 0.17-0.22). Infants receiving CPAP but no HFNC died at an earlier median 
chronological age: CPAP group, 22 (IQR 10-39) days; HFNC group 40 (20-76) days (p< 
0.001). Among survivors, HFNC use was associated with increased odds of 
bronchopulmonary dysplasia (BPD) (aOR 2.98, 95% CI 2.81-3.15) and other adverse 
outcomes. 
 
Conclusions: NIV use is increasing, particularly as initial respiratory support. HFNC use has 
increased significantly with a 7-fold increase soon after birth which was associated with 
higher rates of BPD.  As more infants survive with BPD, we need robust clinical evidence, to 





The dataset was created by the NDAU and this study was approved by Yorkshire & The 
Humber – Sheffield Research Ethics Committee (IRAS 259802). 
 
Key words: nasal continuous positive pressure ventilation; high flow nasal cannula oxygen; 
bronchopulmonary dysplasia 
Abbreviations: aOR, adjusted odds ratio; BPD, bronchopulmonary dysplasia; CPAP, 
continuous positive airway pressure; CI, confidence interval; GA, gestational age; HFNC, 
high flow nasal cannula oxygen; IQR, inter-quartile range; MD, median difference; NEC, 
necrotising enterocolitis; NIV, non-invasive ventilation; NNRD, National Neonatal Research 
Database; ROP, retinopathy of prematurity; SD, standard deviation.   
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What is already known on this topic 
• Non-invasive ventilation (NIV) is being used increasingly to provide respiratory 
support to very preterm infants. 
• While Continuous Positive Airway Pressure (CPAP) remains the mainstay of NIV, 
High flow nasal cannula oxygen (HFNC) is a popular mode of NIV and clinicians 
have reported increasing preference of using HFNC. 
 
What this study adds 
• NIV support, particularly HFNC, in very preterm infants increased significantly 
between 2010 and 2017 in England and Wales. 
• HFNC is increasingly used as initial respiratory support in extremely preterm infants, 
although there is a high rate of such infants requiring CPAP or mechanical ventilation 






In very preterm infants, increased use of antenatal steroids, early surfactant, and attempts to 
minimise lung injury have encouraged increased use of non-invasive ventilation (NIV).[1] 
Modalities such as nasal continuous positive airway pressure (CPAP) that provide a set 
distending pressure prevent some adverse effects associated with mechanical ventilation.[2] 
Similarly, high flow nasal cannula oxygen (HFNC), which delivers a set gas flow, rather than 
a set distending pressure, has become increasingly popular.[3] 
 
Continuous distending pressure directly, or generated via a continuous flow of oxygen-air 
mixture, stabilises the upper airway, maintains lung volumes, and stimulates upper airways 
to maintain a respiratory drive.[1] These mechanisms can reduce the need for prolonged 
invasive ventilation and may reduce the risk of bronchopulmonary dysplasia (BPD) and other 
ventilator-induced lung injuries.[4] Meta-analyses suggest that, when used for initial 
respiratory support or as respiratory support after extubation, HFNC and CPAP are not 
different when comparing the risks of BPD and death in preterm infants.[5] Both are now 
frequently used.  Although UK clinicians’ report increased use of HFNC [6], there are no data 
quantifying the change in use of NIV in actual practice.  
 
We aimed to quantify the change in use of NIV in infants born at <32 weeks’ gestation 
across England and Wales from 2010 to 2017 and analysed the association between these 
changes and clinical outcomes. 
 
Methods 
We performed a retrospective cohort study of infants born at <32 weeks’ gestation in 
England and Wales from 01 January 2010 to 31 December 2017 inclusive, whose data are 




Infants were excluded if there were missing data as described in Supplementary Figure 1 
and Supplementary Table 1.[7]. 
 
Exposures 
From variables that record types of respiratory support received (invasive ventilation, NIV, 
supplemental oxygen, type of NIV), we identified infants who received any NIV 
(Supplementary Table 1). Infants who received NIV were divided into two groups – those 
who received HFNC for any length of time (HFNC group) and those who received CPAP and 
had no record of receiving HFNC (CPAP only group). Infants in the HFNC group may have 
received CPAP also. 
 
Outcomes 
BPD was defined as requiring any supplementary oxygen or respiratory support at 36 
weeks’ CGA (infants who died before 36 weeks were excluded) [9]. Other pre-planned 
outcomes and their definitions are given in Supplementary Table 1.  
 
Statistical Analysis 
All data management and analyses were performed using STATA, version 15.1 (StataCorp, 
College Station, Tx). After exclusions, we quantified the percentage of all admissions each 
year where HFNC was used, both for all infants and for two pre-specified subgroups: those 
born at <28 weeks’, and those born at 28-31 weeks’ gestation. We compared the study 
groups, including demographic, pregnancy and delivery and the NMR-2000 score to 
describe infants’ risk of in-hospital mortality.[10]  
 
We quantified and described changes in the highest mode of respiratory support received on 
the first day after birth. We described the percentage who subsequently ‘failed’ on the initial 
mode as those who had escalation of respiratory support within 7 days i.e., for those on 
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HFNC initially, if they received CPAP and/or mechanical ventilation and for those on CPAP 
initially, if they received mechanical ventilation. Where HFNC was not the initial mode of 
respiratory support, we quantified subsequent exposure to HFNC. Change in use over the 
study period (2010-2017) was analysed using the Chi-squared test for trends. 
 
We used logistic regression for binary variables and quantile regression for continuous 
variables to explore the association between study groups and the pre-specified outcomes. 
Odds ratios and median differences (MD) were adjusted for: GA group (<28 weeks’ 
gestation or 28-31 weeks’ gestation); sex; birth weight for age z-score (<-2SD or ≥-2SD or 
between <2SD and ≥-2SD); exposure to antenatal steroids; NMR-2000 category (low risk, 
medium risk or high risk)[10]; need for mechanical ventilation on day 1; and year of 
admission. Any missing data for confounding variables were treated as separate categories 
and infants retained in the models. We used a robust variance estimator to account for 
clustering of infants within units. All P values were 2-sided, significance was set at P<0.05, 
and we used a Bonferroni correction to account for multiple testing. A predefined subgroup 
analysis was performed for all outcomes for infants born at <28 weeks’ gestation and those 
born at 28-31 weeks’ gestation.  
 
This study was approved by Yorkshire & The Humber – Sheffield Research Ethics 





From the population of 63,210 infants born at <32 weeks’ gestation, 56,537 infants were 
retained after exclusions (Supplementary Figure 1). Of these, 45,898 infants received NIV.   
 
Non-invasive ventilation (CPAP or HFNC) on day of birth  
On the day of birth, 16,308/56,537 (28.8%) infants received NIV, which included 
1,065/17,061 (6.2%) infants <28 weeks and 15,243/39,476 (38.6%) infants of 28-31 weeks’ 
GA. During the study period, those who received NIV on the first day increased from 
1,457/6,479 (22.5%) to 2,598/7401 (35.1%). This increase was larger among the 28-31 
weeks’ GA group [(from 1,357/4,570 (29.7%) to 2,471/5,194 (46.5%)] as compared to that 
among infants <28 weeks’ GA [from 100/1,909 (5.2%) to 181/2,216 (8.2%)]. 
 
Figure 1 shows the respiratory support received by the infants on the first day (initial 
respiratory support) from 2010 to 2017. The percentage receiving CPAP increased 1.3-fold 
from 21.5% to 28.0% whilst HFNC use increased by 7-fold from 1.0% to 7.0%. This increase 
was seen both in infants born at <28 weeks’ and those born at 28-31 weeks’ GA, though the 
magnitude of increase was greater amongst the latter (Table 1). 
 
CPAP was used as initial support in 14,312/56,537 infants (25.3% of all admissions) of 
whom 18.3% (n=2,623/14,312) went on to receive mechanical ventilation within 7 days 
(Table 1). The failure rate was higher among infants born at <28 weeks, of whom 263/836 
(31.5%) were ventilated within 7 days compared to 2,360/13,476 (17.5%) infants born at 28-
31 weeks.  
 
HFNC was used as the initial respiratory support in 1,996/56,537 infants (3.5% of all 
admissions). 748/1,996 (37.5%) went onto receive CPAP (n=571/1,996 [28.6%]) or 
mechanical ventilation (n=347/1,996 [17.4%]) within 7 days, including 170/1,996 (8.5%) who 
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received both CPAP and mechanical ventilation. The failure rate was higher among the 
more immature infants [<28 weeks’ GA: 135/229 (59.0%), including 84/229 (36.7%) who 
were mechanically ventilated; 28-31 weeks’ GA: 613/1,767 (34.7%), including 263/1,767 
(14.9%) who were mechanically ventilated]. Among the infants who received HFNC on the 
first day, those who “failed” included more infants who were extremely preterm i.e. <28 
weeks’ (135/784 [18.0%] vs. 94/1248 [7.5%] p<0.001); of lower birth weight [1,285 (346) g 
vs. 1396 (318) g; p<0.001]; multiple births (35.2% vs. 28.2%; p=0.001); born by Caesarean 
section (64.7% vs. 55.4%; p<0.001); had prolonged rupture of membranes (17.8% vs. 
28.6%; p<0.001); and who had not had surfactant (15.0% vs. 9.5%; p<0.001). There was no 
difference in the sex of the infants or receipt of antenatal steroids.  
 
CPAP use during neonatal care 
The use of CPAP at any point during an infant’s stay in neonatal care significantly increased 
from 68.5% infants in 2010 (n=4,439/6,479) to 80.2% in 2017 (n=5,941/7,410) (chi-squared 
test for trend p<0.001). Further data on the use of CPAP in infants who received mechanical 
ventilation as initial respiratory support are described in Table 2. 
 
HFNC use during neonatal care 
The use of HFNC at any point significantly increased from 14.3% of infants in 2010 
(n=928/6,479) to 68.0% in 2017 (n=5,039/7,410) (Figure 2, p<0.001). The increase in 
percentage of infants who received mechanical ventilation or CPAP as their initial respiratory 
support and then went on to receive HFNC, and data demonstrating earlier and more 
prolonged use of HFNC, are described in Table 2. 
 
Clinical outcomes associated with use of CPAP and HFNC  
There were 18,926 infants who had CPAP only and 26,936 infants who received any HFNC 
(Supplementary Figure 1).  Infants receiving HFNC were more immature and smaller at 
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birth, more were exposed to antenatal steroids and received surfactant while a smaller 
proportion were delivered by caesarean section, were multiple births, and were less likely to 
be born to mothers who had prolonged rupture of membranes (Supplementary Table 2). 
 
The outcomes are shown in Table 3 and by sub-group in Supplementary Tables 3 and 4. 
The odds of death before discharge were significantly higher in infants who had CPAP only 
compared to those who had any HFNC (aOR, 0.19 [95% CI, 0.17 to 0.22]). Infants who had 
CPAP only died at an earlier chronological age than those who received HFNC (median 
[IQR] age of death: CPAP group, 22 [10 to 39] days; HFNC group, 40 [20 to 76] days; p< 
0.001) (Supplementary Figure 2). Excluding deaths before 36 weeks CGA, 3,136/18,003 
(17.4%) infants who had CPAP only developed BPD compared to 12,336/26,260 (47.0%) 
who received any HFNC. The odds of developing BPD were significantly higher in the HFNC 
group (adjusted odds ratio odds ratio [aOR], 2.98 [95% CI, 2.81-3.15]). Infants who had 
HFNC spent significantly longer on respiratory support, had longer hospital stay, higher odds 




We found that, in England and Wales, there have been significant changes in the use of NIV 
in very preterm infants with substantial increase in use of HFNC from <15% of all infants 
born at <32 weeks’ gestation in 2010 to 68% in 2017, both as initial respiratory support (from 
1% to 7%) and as support received later (from 15.7% to 69.8%). This is similar to the trend 
seen in Australia and New Zealand.[11] 
 
Use of NIV on the day of birth has increased from 22% to 35% over the study period 
although, overall, only 8% of those born <28 weeks’ gestation received NIV on this day. In 
an Australia-New Zealand cohort (2007-2013), 29% of infants <29 weeks’ gestation received 
CPAP for initial respiratory support, 43% of whom required mechanical ventilation within 72 
hours. [12] The overall CPAP failure rate was lower in our cohort (31%) even though we 
measured failure over a longer 7-day period. Systematic reviews of RCTs comparing early 
prophylactic CPAP with mechanical ventilation show a nearly 50% reduction in need for 
mechanical ventilation [13]. Our data demonstrate a more conservative use of CPAP as the 
initial respiratory support in England and Wales.   
 
The Cochrane systematic review did not find any study that investigated the use of HFNC as 
the initial mode of respiratory support in infants <28 weeks’ gestation while other reviews 
reported that HFNC has higher failure rates than CPAP when used as first-line support in 
<28 week infants [14][15]. We found that 60% of <28 weeks’ gestation infants who received 
HFNC as initial support subsequently required escalation of support within 7 days, compared 
to 31.5% of the CPAP group. In the sub-group of infants born at 28-31 weeks’ gestation, 
34.7% who received HFNC as initial mode required escalation within 7 days. This is similar 
to the 32.9% failure rate for HFNC among 28-31 week infants reported by Roberts et al. [16] 
in an RCT that was stopped early due to the high rate of HFNC treatment failure. When 
CPAP was used as initial mode of respiratory support, we found that 17.5% were ventilated 
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within 7 days, similar to the rate reported by Roberts et al. (16.1%) although they measured 
rates of intubation up to 72 hours only. HFNC use as the initial respiratory mode is 
increasing in popularity particularly in more mature infants. In a two-centre study in the UK, 
Zivanovic et al., found that use of HFNC without the need for CPAP as “rescue” was 
successful in preventing intubation in infants between 28 and 36 weeks’ gestation.[17] 
 
Similarly, we found an increase in the use of HFNC later in neonatal care with significant 
increases in the number of infants who received any HFNC and the number of days on 
HFNC per infant. In addition, we also found that HFNC was given increasingly earlier with 12 
days difference in initiation between 2010 and 2017. 
 
We analysed the associations of these changes in practice with clinical outcomes and found 
higher mortality among infants who never received HFNC. Among those who survived to 36 
weeks CGA, we found that the adjusted odds of BPD were significantly higher among those 
who received HFNC compared to those who had CPAP only. Infants in the CPAP only group 
died significantly earlier than those in the HFNC group. It is possible that attending clinicians 
did not choose HFNC for infants with more disease in the first few weeks of life. Such infants 
remained on mechanical ventilation or CPAP and may have died before they were 
considered well enough to receive HFNC. The survivors, particularly those who required 
prolonged respiratory support, were then more likely to receive HFNC, resulting in a higher 
rate of both survival and BPD amongst them. This suggests an element of confounding by 
indication i.e. the differences in outcome are related to the way a particular intervention is 
used rather than the intervention itself, which may explain some of the relationship between 
HFNC and death and HFNC and BPD. However, the use of HFNC may also be a step in the 
causal pathway [18] of BPD. The variable and unregulated distending pressure generated by 
HFNC may cause uncontrollable overexpansion and/or atelectasis that aggravate lung injury 
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leading to higher risks of BPD. Meta-analysis of RCTs, showed no difference in BPD 
between HFNC and CPAP use although the studies did not include many infants born at <28 
weeks’ gestation [5]. Our findings are similar to previous smaller observational studies.[19] 
Other important clinical outcomes such as late onset sepsis, NEC, PDA, pneumothorax, and 
ROP were also more frequent in babies who received HFNC. Infants who received HFNC 
required respiratory support for longer and received in-hospital neonatal care for longer. 
Prolonged need for respiratory support with HFNC has been demonstrated in meta-analyses 
of RCTs [5] and observational studies. [19,20]. Our study, due to its retrospective, 
observational design, cannot show a direct link between choice of NIV and any of the clinical 
outcomes we report. It has been suggested that the increased perceived patient tolerance, 
and ease of application and maintenance, may result in less urgency to wean leading to 
longer lengths of respiratory support and hospital stay [21]. 
 
Our study of 56,537 infants, limited by observational design, cannot imply a causative link 
between HFNC and either reduced mortality or increased BPD as highlighted by Roberts et 
al.[22] RCTs remain the gold-standard for demonstrating causation and clinical trials suggest 
that HFNC does not increase the risk of death or BPD compared to CPAP at least in the 
more mature population [5]. However outcomes in research trials can be superior to the 
same practice in clinical situations, possibly due to the greater level of control over patient 
selection and better adherence to treatment protocols in trial settings [23]. The worse 
outcomes, such as increased odds of BPD, in observational studies may be a consequence 
of indication creep [24] and outcomes may also vary with experience and training of 





With a database that covers almost the entire population of England and Wales, we 
achieved a large sample size that enabled us to quantify the changes comprehensively and 
account for several confounding variables. In addition, we have accounted for multiple 
testing and used a robust variance estimator to account for clustering of infants within units. 
These make a robust observational study but do not remove the inherent limitation that 
associations do not imply causation.  
 
Conclusion 
NIV use is increasing. CPAP use increased 1.3-fold while HFNC use increased by 7-fold as 
respiratory support soon after birth.  As more infants survive with BPD, we need clinical 
evidence and ongoing monitoring to ensure practice evolves in keeping with the best 
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Table 1. NIV support use on day of birth and rates of requiring escalation in respiratory 






Received HFNC as  
initial support* n (%) 
Received CPAP as  




















7 days n (%) 
Infants born at <32 weeks’ gestational age 
2010 6,479 63 (1.0) 16 (25.4) 11 (17.5) 1,394 (21.5) 203 (14.6) 
2011 6,929 97 (1.4) 42 (43.3) 17 (17.5) 1,660 (24.0) 302 (18.2) 
2012 6,981 113 (1.6) 49 (43.4) 22 (19.5) 1,685 (24.1) 298 (17.7) 
2013 7,081 183 (2.6) 78 (42.6) 36 (19.7) 1,730 (24.4) 325 (18.8) 
2014 6,963 248 (3.6) 102 (41.1) 47 (19.0) 1,831 (26.3) 354 (19.3) 
2015 7,317 356 (4.9) 149 (41.9) 67 (18.8) 1,950 (26.7) 377 (19.3) 
2016 7,377 415 (5.6) 146 (35.2) 64 (15.4) 1,985 (26.9) 374 (18.8) 
2017 7,410 521 (7.0) 166 (31.9) 83 (15.9) 2,077 (28.0) 390 (18.8) 









Subgroup of infants born at <28 weeks’ gestational age 
2010 1,909 12 (0.6) 4 (33.3) 3 (25.0) 88 (4.6) 26 (29.5) 
2011 2,150 21 (1.0) 9 (42.9) 6 (28.6) 97 (4.5) 28 (28.9) 
2012 2,171 19 (0.9) 13 (68.4) 7 (36.8) 103 (4.7) 34 (33.0) 
2013 2,092 16 (0.8) 11 (68.8) 7 (43.8) 82 (3.9) 27 (32.9) 
2014 2,092 22 (1.1) 19 (86.4) 14 (63.6) 106 (5.1) 45 (42.5) 
2015 2,199 39 (1.8) 26 (66.7) 14 (35.9) 110 (5.0) 36 (32.7) 
2016 2,232 44 (2.0) 22 (50.0) 11 (25.0) 125 (5.6) 36 (28.8) 
2017 2,216 56 (2.5) 31 (55.4) 22 (39.3) 125 (5.6) 31 (24.8) 









Subgroup of infants born at 28-31 weeks’ gestational age 
2010 4,570 51 (1.1) 12 (23.5) 8 (15.7) 1,306 (28.6) 177 (13.6) 
2011 4,779 76 (1.6) 33 (43.4) 11 (14.5) 1,563 (32.7) 274 (17.5) 
2012 4,810 94 (2.0) 36 (38.3) 15 (16.0) 1,582 (32.9) 264 (16.7) 
2013 4,989 167 (3.3) 67 (40.1) 29 (17.4) 1,648 (33.0) 298 (18.1) 
2014 4,871 226 (4.6) 83 (36.7) 33 (14.6) 1,725 (35.4) 309 (17.9) 
2015 5,118 317 (6.2) 123 (38.8) 53 (16.7) 1,840 (36.0) 341 (18.5) 
2016 5,145 371 (7.2) 124 (33.4) 53 (14.3) 1,860 (36.2) 338 (18.2) 
2017 5,194 465 (9.0) 135 (29.0) 61 (13.1) 1,952 (37.6) 359 (18.4) 









*mode of respiratory support on day of birth 




Table 2. Use of HFNC and CPAP for respiratory support following support with mechanical 



























and CPAP,  
median 
(IQR) 
HFNC use following initial mechanical ventilation or CPAP 
2010 5,030 792 (15.7) 6 (2-14) 17 (6-45) 1 (1-2) 
2011 5,556 1,794 (32.3) 8 (2-20) 18 (5-40) 2 (1-4) 
2012 5,741 2,269 (39.5) 9 (3-23) 14 (5-34) 2 (1-4) 
2013 5,905 2,994 (50.7) 11 (4-25) 9 (3-27) 2 (1-5) 
2014 5,870 3,494 (59.5) 12 (4-28) 7 (3-22) 3 (1-6) 
2015 6,136 3,950 (64.4) 14 (5-29) 6 (3-19) 3 (1-7) 
2016 6,222 4,255 (68.4) 13 (5-28) 5 (2-15) 3 (1-7) 
2017 6,239 4,357 (69.8) 13 (5-29) 5 (2-14) 3 (1-7) 
All 46,699 23,905 (51.2) 11 (4-27) 7 (3-23) 3 (1-6) 










days of CPAP 
received, 
median (IQR) 




2010 3,636 2,708 (74.5) 13 (4-29) 3 (2-7) 
2011 3,896 2,989 (76.7) 14 (4-31) 3 (2-6) 
2012 4,056 3,202 (78.9) 14 (5-30) 3 (2-6) 
2013 4,175 3,407 (81.6) 11 (4-26) 3 (2-6) 
2014 4,039 3,331 (82.5) 12 (4-27) 3 (2-7) 
2015 4,186 3,463 (82.7) 11 (4-26) 3 (2-7) 
2016 4,237 3,542 (83.6) 11 (4-25) 3 (2-7) 
2017 4,162 3,465 (83.3) 11 (3-25) 3 (1-7) 
All 32,387 26,107 (80.6) 12 (4-27) 3 (2-7) 
Abbreviations: CPAP, continuous positive airway pressure; HFNC, high flow nasal 





Table 3. Clinical outcomes in infants who received NIV from 2010 to 2017 in England and 
Wales: comparison between those who received any HFNC vs. those who had CPAP only. 






aOR or median 
difference (95% 
CI) 










(2.81 to 3.15)c 









(0.17 to 0.22)c 
BPD or death before 








(2.33 to 2.60)c 






(1.72 to 1.90)c  






(1.26 to 1.43)c 






(1.03 to 1.36)  






(1.73 to 2.50)c 
















(1.06 to 1.44)  






(1.52 to 1.96)c 
















(1.71 to 2.18)c 
Continuous outcomes, median (IQR) 
Number of days of 
invasive ventilationa 2 (0-6) 3 (1-9) 1 (0-3) 
0.0 
(-2.1 to 2.1)c 
Number of days of NIVa 12 (4-36) 24 (8-46) 5 (2-13) 6.3 (5.7 to 6.9)c 
Number of days of 
respiratory supporta 22 (6-61) 41 (11-77) 7 (3-25) 
9.5 
(9.1 to 9.9)c  
Length of stay (days)a 55 (40-80) 66 (47-91) 44 (34-59) 8.7 (8.3 to 9.1)c  
Abbreviations: CI, confidence interval; BPD, bronchopulmonary dysplasia; IVH, 
intraventricular haemorrhage; NEC, necrotising enterocolitis; ROP, retinopathy of 
prematurity; 
aOR, adjusted odds ratio, adjusted for gestational age <28 weeks, sex, birth weight z-score 
<-2, exposure to antenatal steroids, NMR-200 category, mechanical ventilation on day 1, 
year of admission. 
a excluded infants who died before 36 weeks corrected gestational age 
b missing observations: BPD, 8; Death before discharge, 17 





Figure 1. Use of HFNC as the initial mode of respiratory support in infants born at <32 
weeks' gestational age in England and Wales (2010-2017)  
Failure refers to escalation of respiratory support within 7 days i.e. HFNC failed refers to 
those infants who received HFNC as the initial mode of respiratory support but needed 
CPAP and/or mechanical ventilation within 7 days and CPAP failed refers to those who 
received CPAP as the initial mode of respiratory support but needed mechanical ventilation 







Figure 2. Percentage of all infants born at <28 weeks’ gestational age and those born at 28-
32 weeks’ gestational age in England and Wales (2010-2017) who received any HFNC 
during their neonatal care. Image created by authors using STATA, version 15.1 (StataCorp, 





Observational cohort study of changing trends in non-invasive respiratory 
ventilation in very preterm infants and associations with clinical outcomes  
Laura Sanda, BMBS, Lisa Szatkowskia, PhD, T’ng Chang Kwoka, BMBS, Don 
Sharkeya, PhD, David Toddb, PhD, Helen Budgea, PhD, Shalini Ojhaa,c, PhD 
Supplementary information Table 1 online only: List of variables extracted 
from the National Neonatal Research Database (NNRD) and the ICD-10 codes 
used to identify congenital anomaly exclusions and number of babies 
excluded and definitions of exposure and clinical outcomes 




- Gestational age was determined using the variables “GestationWeeks” 
and “GestationDays” 
- Birth weight was determined using the variable “Birthweight” 
- Female sex was determined using the variable “Gender” 
- Multiplicity was determined using the variable “Fetus number” 
- Any antenatal steroid given was determined using the variable 
“Antenatal steroids given” and “Steroids antenatal courses” 
- Caesarean delivery was determined using the variable “Mode of 
delivery”, caesarean section being emergency caesarean section- not in 
labour, emergency caesarean section – in labour, elective section – not 
in labour, elective section – in labour  
- Prolonged rupture of membranes (>18 hours) was determined using the 
variable “Rupture of membranes” 
Surfactant given was determined using the variable “Surfactant given at 
resuscitation” and “Day surfactant given” 
Outcomes - CLD was determined using the variables “Respiratory support”, 
“AddedO2”, “Ventilation mode”, “NonInvasiveRespiratoryS” and 
“Daydateanon” 
- Death before discharge was determined using the variables 
“Dateofdeath” and “Deathagemin” 
- Composite Outcome was determined by CLD or death at 36 weeks’ 
gestation 
- Sepsis was determined by use of antibiotics for ³5 consecutive days 
using the variables “drugsday” and searching for “penicillin, 
flucloxacillin, amoxicillin, gentamicin, metronidazole, meropenem, 
cephalosporin (cefotaxime, ceftazdime, cefradine, ceftriaxone) and 
vancomycin; determined that antibiotic was used for ³5 consecutive 
days by using the variable “dayoflife” 
- Early sepsis was determined by the use of ³5 consecutive days 
antibiotics in the first seven days of life 
- Late sepsis was determined by the use of ³5 consecutive days 
antibiotics after 7 days of life  
- Medical NEC was determined by the variable “nectreatment” coded 
medically for ³5 consecutive days 
- Surgical NEC was determined by the variable “nectreatment” coded as 
surgical 
- Surgical PDA was determined using the variable “treatmentforpda” and 
searching for ‘ligation’ or ‘ligature’ or ‘closure of PDA/ patent ductus 
arteriosus’ or ‘open correction of PDA’ or ‘percutaneous transluminal 
prosthetic occlusion of PDA’ on “principleproceduresduringstay”,  
“principlediagnosisatdischarge” and “diagnosisatadmission” 
- IVH (Grade 3 or 4) was determined using data from cranial ultrasound 
variable “rightivh” and “leftivh” (looking for grade 3 and 4) and searching 
for ‘ivh grade 3’ and ‘ivh grade 4’ and ‘large intraventricular 
haemorrhage’ and ‘intraventricular haemorrhage/ parenchymal 
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haemorrhage’ in variables “diagnosisatadmission” and 
“principaldiagnosisatdischarge” 
- PVL was determined using data from cranial ultrasound variable “pvl” 
and searching for ‘cystic periventricular leucomalacia’ and ‘pvl’ and 
‘periventricular leucomalacia’ in variables “diagnosisatadmission” and 
“principaldiagnosisatdischarge” 
- ROP was determined using variables “principleproceduresduringstay” 
and requiring VEGF and/or laser treatment  
- Pneumothorax was determined by searching ‘pneumothorax’ in 
variables “diagnosisatadmission” and “principaldiagnosisatdischarge” 
- Postnatal steroid was determined by the use of steroids 
(dexamethasone >3 days, hydrocortisone >7 days, methylprednisolone 
>3 days and prednisolone >7 days) using variables “drugsday” and 
“dayoflife” 
- Invasive ventilation was determined by using variables 
“ventilationmode” and “respiratorysupport” 
- Number of days of invasive ventilation was determined using variables 
“ventilationmode” and “respiratorysupport” and “dayoflife” 
- Number of non-invasive ventilation days was determined using 
variables “respiratorysupport” and “noninvasiverespiratorysupport” and 
“dayoflife” 
- Time to first oral feed given was determined using variables 
“dayenteralfeeds” and “formulaname” and “dayoflife” 
- Number of days on the neonatal unit was determined using variables 
“dischtimeanon” and “admittimeanon” 
Infants excluded due to missing information 
Infant were excluded in there was missing information oon gestational age (GA), birthweight 
or sex. Where contradictory data were recorded, the entry at the first admission was selected. 
Infants recorded as born at <22 weeks’ gestation, of birthweight for GA z-score >4, or <-4, 
standard deviations (SD), as admitted >12 hours after birth, had missing records of ≥1 days 
or had congenital anomalies that impact respiratory support listed below.  
ICD-10 codes used to identify congenital anomaly exclusions and number of babies 
excluded 
ICD-10 code Anomaly Number excludeda 
Q00 Anencephaly and similar malformations  
Q01 Encephalocele and similar malformations 8 
Q05 Spina bifida and similar malformations 27 
Q20 Congenital malformations of cardiac chambers and connections 133 
Q21.2 Atrioventricular septal defect (AVSD) 70 
Q21.3 Tetralogy of Fallot 73 
Q21.91 Single atrium  
Q21.92 Single ventricle  
Q22 Congenital malformations of pulmonary and tricuspid valves 236 
Q23 Congenital malformations of aortic and mitral valves 80 
Q25.1 Coarctation of aorta 109 
Q25.2 Atresia of aorta  
Q25.3 Stenosis of aorta (AS) 5 
Q25.4 Other congenital malformations of aorta 49 
Q25.5 Atresia of pulmonary artery 9 
Q25.6 Stenosis of pulmonary artery (PS) 362 
Q25.8 Other congenital malformations of great arteries 2 
Q26.2 Total anomalous pulmonary venous connection (TAPVD) 12 
Q30.0 Choanal atresia 30 
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Q32 Congenital malformations of trachea and bronchus 102 
Q33.0 Congenital cystic lung 45 
Q33.2 Sequestration of lung 6 
Q33.3 Agenesis of lung  
Q33.4 Congenital bronchiectasis  
Q33.5 Ectopic tissue in lung  
Q33.6 Hypoplasia and dysplasia of lung 16 
Q34.0 Anomaly of pleura  
Q34.1 Congenital cyst of mediastinum  
Q34.8 Other specified congenital malformations of respiratory system  
Q35/Q36/Q37 Cleft lip and/or palate 202 
Q39 Oesophageal atresia 104 
Q41 Congenital absence, atresia and stenosis of small intestine 15 
Q42 Congenital absence, atresia and stenosis of large intestine 41 
Q60.1 Bilateral renal agenesis 3 
Q60.6 Potter's syndrome 4 
Q61.1 Polycystic kidney, infantile type 6 
Q61.2 Polycystic kidney, adult type 1 
Q64.1 Exstrophy of urinary bladder 2 
Q64.2 Posterior urethral valves (PUV) 25 
Q64.5 Congenital absence of bladder and urethra 1 
Q77.1 Thanatophoric short stature  
Q79.0 Congenital diaphragmatic hernia 75 
Q79.1 Eventration of diaphragmatic hernia 18 
Q79.2 Exomphalos 66 
Q79.3 Gastroschisis 50 
Q90 Down's syndrome 171 
Q91 Edwards' syndrome and Patau's syndrome 42 
aSum exceeds total number of exclusions as some infants had more than one anomaly 
Defintion of exposure to non-invasive ventilation (NIV) 
From variables that record types of respiratory support received (invasive ventilation, NIV, 
supplemental oxygen, type of NIV), we first identified babies who received any NIV. Those who 
did not receive any respiratory support, had only mechanical ventilation and/or supplemental 
oxygen, or where information was not available to discern the type of NIV were excluded. 
HFNC group:  those who received HFNC for 
any length of time. Infants in the HFNC group 
may have received CPAP also. 
CPAP group: those who received CPAP and 
had no record of receiving HFNC. 
Definition of clinical outomces* 
Bronchopulmonary 
dysplasia (BPD) 
Infant requiring any supplementary oxygen or respiratory support 
at 36 weeks’ CGA (infants who died before 36 weeks were 
excluded) [9] 
Death before discharge Infant death prior to discharge from neonatal care 
Late onset sepsis (LOS) recorded diagnosis with either a positive blood culture or antibiotic given for ³5 consecutive days) after 72 hours of life 
Necrotising 
enterocolitis (NEC) 
recorded diagnosis of confirmed NEC); surgical NEC (NEC 
treatment coded as surgical 
Patent ductus 
arteriosus (PDA) Recorded diagnosis of PDA requiring surgical closure 
Retinopathy of 
prematurity (ROP) 
Recorded diagnosis of ROP requiring vascular endothelial growth 
factor or laser treatment 





Record of infant having received dexamethasone > 3 days, 
hydrocortisone > 7 days, methylprednisolone > 3 days or 
prednisolone > 7 days); 
Number of days of non-
invasive ventilation 
Number of days of care where infants was recorded as having 
received any form of NIV 
Number of days of non- 
respiratory support 
Number of days of care where infants was recorded as having 
received any respiratory support 
Number of days spent in 
neonatal care 
Total number of days infant remained in neonatal care including 
stay in all neonatal units they were cared for in.  
*Code lists are available from the authors on request. 
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Supplementary information Table 2. Characteristics of infants who received NIV 
with HFNC or with CPAP only from 2010 to 2017 in England and Wales, by 
gestational age group. 
 All infants HFNC CPAP only P 
Gestational age <28 weeks n = 13,841 n = 10,734 n = 3,107  
Gestational age  
(weeks, median (IQR)) 26 (25-27) 26 (25-27) 26 (25-27) <0.001 
Birth weight 







Birth weight z-score 
(mean (± SD))a -0.11 (0.86) -0.12 (0.86) -0.07 (0.85) 0.002 
Female sex, n (%) 6,543 (47.3) 5,068 (47.2) 1,475 (47.5) 0.799 
Multiple birth, n (%) 3,339 (24.1) 2,542 (23.7) 797 (25.7) 0.024 
Any antenatal steroid given, n 
(%)a 12,497 (90.3) 9,731 (90.7) 2,766 (89.0) 0.002 
Caesarean delivery, n (%)a 5,605 (40.5) 4,404 (41.0) 1,201 (38.7) 0.008 
Rupture of membranes (>18 












Mechanical ventilation prior to 







NMR-2000 score, categorised as risk of in-hospital mortality, n (%)a 
Low risk 0 (0) 0 (0) 0 (0) 
0.010 Medium risk 9,713 (70.2) 7,555 (70.4) 2,158 (69.5) 
High risk 2,686 (19.4) 2,105 (19.6) 581 (18.7) 
Gestational age 28-31 weeks n = 32,021 n = 16,202 n = 15,819  
Gestational age  
(weeks, median (IQR)) 30 (29-31) 29 (28-30) 30 (29-31) <0.001 
Birth weight 







Birth weight z-score 







Female sex, n (%) 14,340 (44.8) 7,103 (43.8) 
7,237 
(45.7) 0.001 
Multiple birth, n (%) 9,041 (28.2) 4,511 (27.8) 4,530 (28.6) 0.114 
Any antenatal steroid given, n 
(%)b 28,612 (89.4) 14,585 (90.0) 14,027 (88.7) <0.001 
Caesarean delivery, n (%)b 20,424 (63.8) 10,623 (65.6) 9,801 (62.0) <0.001 
Rupture of membranes (>18 







Surfactant given, n (%)b 12,557 (39.2) 6,832 (42.2) 
5,725 
(36.2) <0.001 
Mechanical ventilation prior to 
non-invasive ventilation, n (%) 9,330 (29.1) 5,537 (34.2) 3,793 (24.0) <0.001 
NMR-2000 score, categorised as risk of in-hospital mortality n (%)b 
Low risk  4,047 (12.6) 1,677 (10.4) 2,370 (15.0) 
<0.001 Medium risk  24,094 (75.2) 12,656 (78.1) 11,438 (72.3) 
High risk  533 (1.7) 378 (2.3) 155 (1.0) 
aMissing data amongst babies <28 weeks: birth weight for age z-score, 18 (0.1%); 
exposure to antenatal steroids, 107 (0.8%); born by Caesarean delivery, 683 (4.9%); 
surfactant given, 513 (3.7%); NMR-2000 score, 1,442 (10.4%)  
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bMissing data amongst babies 28-31 weeks: exposure to antenatal steroids, 405 (1.3%); 
born by Caesarean delivery, 1,739 (5.4%); surfactant given, 2,034 (6.4%); NMR-2000 
score, 3,347 (10.5%) 
 
Supplementary information Table 3. Outcomes in infants born at <28 weeks’ gestation 
who received NIV from 2010 to 2017 in England and Wales: comparison between those who 
received HFNC vs. those who received CPAP only.  

















(1.88 to 2.35)c 









(0.10 to 0.14)c 
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(1.37 to 1.67)c 
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(1.48 to 2.18)c 


























(1.66 to 2.29)c 
















(1.40 to 1.82)c 
Continuous outcomes, median (IQR) 
Number of days of 
invasive ventilationa 10 (3-25) 10 (3-26) 7 (2-19) 2.0 (1.3 to 2.7)
c 
Number of days of NIV 
ventilationa 45 (31-60) 47 (34-63) 35 (22-47) 11.0 (9.9 to 12.1)
c 
Number of days of 
respiratory supporta 78 (53-103) 81 (57-105) 64 (41-89) 
17.0 (15.1 to 
18.9)c 
Length of stay (days)a 92 (76-113) 94 (77-115) 84 (69-103) 11.0 (9.6 to 12.4)c 
Abbreviations: IQR, interquartile range; BPD, bronchopulmonary dysplasia; IVH, 
intraventricular haemorrhage; NEC, necrotising enterocolitis; ROP, retinopathy of 
prematurity 
aOR, adjusted odds ratio, adjusted for sex, birth weight z-score <-2, exposure to 
antenatal steroids, NMR-200 category, mechanical ventilation on day 1, year of 
admission. 
a excluded infants who died before 36 weeks corrected gestational age 
b missing observations: BPD, 0; Death before discharge, 4 







Supplementary information Table 4. Outcomes in infants born at 28-31 weeks’ gestation 
who received NIV from 2010 to 2017 in England and Wales: comparison between those who 
received any HFNC and those who received CPAP only. 
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(1.73 to 2.69)c 






(2.79 to 7.81)c 


























(1.03 to 1.64) 
















(2.90 to 5.10)c 
Continuous outcomes, median (IQR) 
Number of days of 
invasive ventilationa 1 (0-2) 1 (0-3) 1 (0-2) 0.0 (-8.2 to 8.2) 
Number of days of NIVa 7 (3-15) 10 (5-24) 4 (2-8) 6.0 (5.8 to 6.2)c 
Number of days of 
respiratory supporta 10 (4-29) 17 (7-42) 6 (3-15) 8.8 (8.3 to 9.2)
c 
Length of stay (days)a 46 (36-60) 51 (39-66) 42 (33-52) 8.0 (7.5 to 8.5)c 
Abbreviations: IQR, interquartile range; BPD, bronchopulmonary dysplasia; IVH, 
intraventricular haemorrhage; NEC, necrotising enterocolitis; ROP, retinopathy of 
prematurity 
aOR, adjusted odds ratio, adjusted for sex, birth weight z-score <-2, exposure to 
antenatal steroids, NMR-200 category, mechanical ventilation on day 1, year of 
admission. 
a excluded infants who died before 36 weeks corrected gestational age 
b missing observations: BPD, 8; Death before discharge, 13 





Supplementary information Figure 1. Very preterm infants who received NIV in 







Supplementary information Figure 2. Survival curve for infants born at <32 
weeks’ who received any NIV during their neonatal care in England and Wales in 
2010 to 2017: comparison between those who received HFNC and those who 
received CPAP 
 
 
